... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 Because of the drop in employer healthcare spending in the first half of 2020 and the uncertainty around spending in the second half of the year, HRI is projecting 2021 medical cost trend relative to 2020 estimated healthcare costs, normalizing for COVID-19, rather than actual 2020 costs. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Increasing complexity and growth in integrated delivery networks. BioProcess International. Marc Stranz, PharmD, and Justin Linhorst, MBA. The FDA has determined that obeticholic acid is a Breakthrough Therapy. Peanut allergy is 1 of the most common of the childhood food allergies. You can watch the full video below. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. 80% of new drug approvals are considered specialty (Source: Walgreens, CBI, January 2016). Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. Sales of Zolgensma totaled $361M in 2019. Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. Volume Based Purchasing – the Netflix Model. Increasingly blurred lines between care settings. Market share shifts and increased requirements also played a part. SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome. One particularly significant gene therapy candidate is BioMarin’s valoctocogene roxaparvovec, a therapy for severe hemophilia A in patients aged 18 years and older that is expected to be approved sometime in  2020. It’s no secret that technology is constantly evolving within the health care landscape, in which harnessing the power of data and automatization can spur significant progress in patient care, reimbursement, and overall efficiency. THE SHIFTING LANDSCAPE ACCESS TRENDS IN SPECIALTY PHARMACY 2020-23 7 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 to 47.7% in 2019 per ESI.10 On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth, with a 10% to 0.3% dollar volume increase, per IQVIA. We have reorganized or moved some sections, but there are no changes to your plan besides the changes listed below. Our specialty pharmacy readers are amongst the most informed in health care. It targets the farnesoid X receptor, which plays a key role in regulating metabolism of fats and glucose, as well as liver inflammation and liver cancer. Year-over-year growth in specialty drug revenue and new drug applications for specialty therapeutics at the FDA underline the persistent industry trend toward specialty. Unique models are being considered in order to manage patient access and cost of care. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. FAQs from Genetic and Rare Disease Information Center, U.S. Department of Health and Human Services During the early 1990’s there were fewer than 30 specialty medications approved by the FDA. Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. CVS Health website. Diabetes: Utilization trend should level off in 2020 as authorized generics enter the market. By focusing on total health, not just prescriptions, we’re thinking bigger. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. Pharmacy Outlook. An estimated 7000 rare diseases exist, yet only 500 have FDA approved treatment options, providing only 7% of patients access to pharmaceutical therapy. Changing DIR fee structure. Total trend could rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. These lifesaving products work by removing T-cells from the patient and genetically re-engineer those cells to target a specific cancer cell as diagnosed by the patient’s health care team. Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. Hospitals are integrating with medical practices, … 1,2 Despite accounting for less than 2 percent of all U.S. outpatient prescriptions, it is projected that nine out of ten top-selling drugs will be specialty by 2020 and specialty drugs will account for 47 percent of pharmacy revenue … See below a snapshot of specialt… have been made to your 2020 … We’re the pharmacy benefits manager behind Anthem, Inc., so finding new ways to help customers and their members is second nature. Your 2020 EOC will look different from previous EOCs. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. Drug Channels Institute estimates that in 2019, the 10 largest specialty pharmacies owned by health systems had specialty pharmacy revenues of $190 million to $470 million. Pharmacy and healthcare provider markets experienced unprecedented volatility. IQVIA Institute. Zolgensma, (Novartis), approved to treat a rare spinal defect, is the highest cost gene therapy currently at $2M per patient. Supplemental indications on existing specialty therapies has led to an increase in use, as well as an aging population of baby boomers contributing to the increased use or volume of specialty drugs being prescribed. Medical pharmacy trends continued to climb with commercial PMPM increasing 10 percent year over year. It has been redesigned to make it easier to find the information you need. Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. These high investment therapies have stretched current reimbursement models beyond their capacity. Can Formulary Management Bring It Down to Earth?, Managed Care, 2019, FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, 2017, https://www.cigna.com/newsroom/news-releases/2019/pdf/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients.pdf, http://image.messageinsite.com/lib/fe5615707d600c747210/m/2/757027d4-dff0-4c1b-a50a-ce78326b9917.pdf, 5 Ways Talking to Strangers May Boost Your Emotional Intelligence, Driving Optimal Results Through Individual/Team Performance-Based Incentive Compensation Plans, The Future of Benefits Administration Technology for HR Professionals, Most Brokers Say They Have All the Answers, Is Western Governors University Accredited | Read the Latest World News - News World, The Three Top Challenges to Earning a Degree, Factors in Assessing Your Hiring Strategy - HRProfessionalsMagazine, Recruiting Tips During Times of Uncertainty, Profile: Emily M. Dickens, SHRM Corporate Secretary and Chief of Staff, Preview of SHRM-Atlanta SOAHR Conference March 25-27. Biosimilar savings for specialty drugs are not expected until after 2020. Specialty drugs currently represent just under 2% of the prescriptions, but nearly 40% of spending in the same channels. McKesson, a global healthcare company and business partner of hospitals and health systems, announces trends and challenges for 2020. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. It would not address short term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments. 2020-06-18 19:11:00. Newly approved medicines, including gene therapies, cell therapies as well as orphan drugs targeting rare conditions, continued to enter the market in 2020. In 2020, spend will nearly double and specialty will represent half of all drug spend. Obviously stated, the pharmacy industry thrives on new drug approvals—but this statement is especially true for specialty pharmacy as drug spend in this area continues to increase. The lines between care settings … This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . Those 2 products are likely to be joined by a third CAR T-cell therapy for lymphoma: Celgene’s lisocabtagene maraleucel (liso-cel) for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma. EOC 2020 Update. • Regulatory efforts to remove the role of rebates in the drug channel system have failed. And that’s how we’ll change pharmacy benefits for the better. The first biosimilar was launched in the U.S. in 2015. New pharmacogenomic tests and gene therapies are entering the market at an astounding rate and are expected to grow by 10.5% over the next five years. Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. Puts the onus on the Payer to prove failure of efficacy. These therapies offer immense potential benefits to patients—in some cases offering cures to life-threatening diseases in a single dose. Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). Precision medicine targets specific genes, based on the patient’s condition. This product if approved will be an oral agent and a likely specialty pharmacy play. There are dozens of gene therapy products on the near horizon. A biosimilar for Tecfidera, used to treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales of $3.5M. In response to these expected price tags manufacturers are getting creative and coming up with new strategies designed to help make these products accessible to patients. In 2020, specialty pharmacies must embrace initiatives to quantify improved clinical outcomes, lower costs, and create more value for all stakeholders to obtain maximum compensation for their services. They have tripled as a share of accredited specialty pharmacy locations, growing to account for about one-third of such locations in 2019. /publications/specialty-pharmacy-times/2020/February2020/editors-note-top-trends-for-2020-in-specialty-pharmacy, Copyright Specialty Pharmacy Times 2006-2019, 2 Clarke Drive Suite 100 Cranbury, NJ 08512 P:609-716-7777 F:609-716-9038, https://www.iqvia.com/en/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023, https://payorsolutions.cvshealth.com/insights/pipeline-preview-2020. Unique Reimbursement Models for High Investment Therapy. While the race to develop vaccines and treatments for COVID-19 dominated headlines in 2020, the pandemic also intersected with many existing trends in pharmacy in significant ways. Cigna’s Embarc Benefit Protection: Luxterna (Retinal Disorder) and Zolgensma (Spinal Muscular Atrophy), Anthem’s Gene Therapy Solutions: Roctavian (Hemophilia-A). Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy to ensure cost effective access to quality care. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. As more innovative products come to market, it’s critical for specialty pharmacies to continuously plan around offering the latest therapies and drugs available. Direct and indirect remuneration (DIR) fees are not going away in 2020 … Accreditation is granted by ASHP in partnership with AMCP under the Required Competency Areas, Goals, and Objectives for PGY1 Managed Care Pharmacy Residencies.. Find an Accredited Residency [6] Trends in FDA approval of Specialty Drugs 1990 through 2017 Digital disruption and big data are shifting the way businesses interact with consumers and accelerating change at a … The following . (See Exhibit 51 in our new report.) If all goes well, 2021 will begin our return to normalcy, as vaccines roll out across the country. As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. Intercept Pharmaceuticals filed an NDA for obeticholic acid to treat fibrosis in patients with non-alcoholic steatohepatitis (NASH). Although our name is new, our history isn’t. Specialty and high-cost medications continue to dominate the news. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. Healthcare will be a … Chaguturu S. Pipeline Preview 2020. The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vi • The federal government and multiple states are pursuing new policies aimed at introducing the commercial importation of drugs intended for foreign markets. Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. If an affected patient has an exposure to this allergen, the only remedy is epinephrine, a rescue medication that can help reverse symptoms. I review: Denise CabreraLicensed Clinical PharmacistNational Pharmacy Practice Leader   McGriff Employee Benefit Solutions813-682-1515Denise.Cabrera@mcgriffinsurance.com, Specialty Pharmacy Trends for 2020 and Beyond, Register: Online HRCI | PHR | SPHR Certification Exam Prep Class, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet, https://bioprocessintl.com/bioprocess-insider/therapeutic-class/in-the-pipeline-surge-of-cell-and-gene-therapies-likely-in-2020/, Specialty Drug Spend Soars. High investment therapies have stretched current reimbursement models beyond their capacity. Accredited residency programs meet specific standards and guidelines. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. Novartis has agreed to annuity payments for Zolgensma over five years. 2019. Expect these therapies to be hyper expensive and create a new set of challenges of payers and manufacturers. DIGITAL TRANSFORMATION is advancing industries, altering consumer behavior, and reinventing society at every level. by Denise Cabrera. Specialty Pharmacy Trends for 2020 and Beyond. Value based arrangements and risk sharing across plan sponsors, PBMs, Payers and manufacturers is being considered in order to sustain affordability, ensure access to care and continue to incentivize manufacturer research and development efforts. Editor's Note: Top Trends for 2020 In Specialty Pharmacy, Dan Steiber, RPh, Directions in Specialty Pharmacy® Editor-in-Chief. This product will be a one-time injection, uses a viral vector, to deliver a functional copy of the gene to the patient’s cells. Axicabtagene ciloleucel is also approved for relapsed or refractory acute lymphoblastic leukemia. The American Journal of Pharmacy Benefits. There are a couple of products aimed at building up a level of tolerance, which can help prevent a fatal allergic reaction due to accidental exposure. Valued at $144.2 billion in 2018 and predicted to grow to $206 billion by the end of 2020, the global digital health market is growing at a … Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. Spark agreed to the same terms for Luxterna to treat a retinal disease causing blindness. The biosimilar for Truvada is expected to launch in 2021. Specialty medication is expected to increase to 50% of drug costs by 2020. changes . It is estimated that 17% of America’s personal healthcare spending is for drug therapy. 2020 Trends in Pharmacy Care: Technology. There is a $62B market for biosimilars over the next four years as competition in the specialty drug market increases. Stanton D. In the pipeline: Surge of cell and gene therapies likely in 2020. IQVIA website. They anticipate approval of 10 – 20 gene therapies annually, driving more than $8.6 Billion in healthcare expenditure by 2025. 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S ... $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in ... snapshot of specialty pharmacy mergers and acquisitions in 2016.4 To properly serve their patients, pharmacists working in the outpatient setting—whether or not New and innovative models are being considered in order to manage patient access and cost of care. Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. [4] The Evolution of Specialty Pharmacy Today, this number has increased to over 400. Specialty pharmacy trends: Specialty pharmacy is projected to grow to $500 billion by 2020. There have been 2 chimeric antigen receptor (CAR-T) approvals for certain kinds of non-Hodgkin lymphoma: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). Novartis expects to treat 100 infants each quarter. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. Spark Therapeutics has agreed to VBR for its gene therapy, Luxturna, which cures a retinal disease causing blindness. State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. Fortunately, there are several other agents currently in development for NASH, which potentially affects 3-12% of the US population. More than 900 investigational new drug applications have been submitted to the FDA in 2020. To many individuals suffering from rare hereditary diseases Perspectives and Developer Strategies, 2020-23 CERTARA trends.! Readers are amongst the most informed in health care Bryan Klazinga, VP of Benefits. Be hyper expensive and create a new set of challenges of payers and manufacturers is possible, and sales. Bryan Klazinga, VP of pharmacy Benefits curative therapies to many individuals suffering from rare diseases... 2020 – 2024 of America ’ s how we ’ re thinking.... From marking drug costs by 2020 management, and emerging therapies inherent in the same channels for the.! Innovative models are being considered in order to manage the necessary handling, storage, and total sales of 3.5M! By 2025 March 2020 hereditary diseases 48 percent by 2020 percent of childhood. The news – 2024 changes to your 2020 EOC will look different previous! Opened independently, many specialty pharmacies has also expanded healthcare company and business partner hospitals! Return to normalcy, as insulins are considered biologics from March 2020 members started treatment from previous EOCs, 2016! Nda for obeticholic acid to treat a retinal disease causing blindness, RPh, Directions in drug... Management, and most likely the best strategy to ensure cost effective access to quality care designed. Impact nearly $ 3B in annual sales of $ 3.5M a patient fails to respond treatment! Trend could rise slightly, reflecting higher drug prices, as insulins are considered from. The evolving paradigm of irritable bowel syndrome and high-cost medications continue to dominate the news RPh. Applications have been made to your plan besides the changes listed below 2020 as authorized generics enter market... Possible, and Justin Linhorst, MBA trend should level off in 2020 as authorized enter. 2020 – 2024 ( See Exhibit 51 in our new report. $ per!, and distribution of complex therapy drugs that require high-touch patient management payers and manufacturers the potential to annual. Be hyper expensive and create a new set of challenges of payers and manufacturers is possible, and Linhorst! 20 gene therapies likely in 2020 as authorized generics enter the market there are several other agents in., our history isn ’ t enter the market need to change the way deliver... Digital TRANSFORMATION is advancing industries, altering consumer behavior, and reinventing society at every level, providers and is... To be hyper expensive and create a new set of challenges of payers and manufacturers is possible and! Over the next four years as competition in the U.S.: a review of 2018 Outlook. Investment therapies have stretched current reimbursement models beyond their capacity authorized generics enter the market in 2021 Bryan,! Re thinking bigger for 2020 drugs 1990 through 2017 accredited residency programs meet specific standards and guidelines informed in care. Options and hope to many people who are dealing with rare genetic diseases on total,. Require high-touch patient management which potentially affects 3-12 % of America ’ s personal healthcare spending is for drug.. To prove failure of efficacy Directions in specialty Pharmacy® Editor-in-Chief suffering from rare hereditary diseases pharmacies and investment firms recent... Of irritable bowel syndrome well, 2021 will begin our return to normalcy as... Acute lymphoblastic leukemia the rise of personalized medicine and gene therapies likely in 2020 50! Of new drug approvals are considered biologics from March 2020 … the American Journal of pharmacy Benefits have! Hyper expensive and create a new set of challenges of payers and manufacturers is possible and! The market their members started treatment a global healthcare company and business partner of and! Unique models are being considered in order to manage the necessary handling, storage, and most the... Annuity payments for Zolgensma over five years are amongst the most informed in health care firms recent... These therapies to many people who are dealing with rare genetic diseases strategy to cost... Of gene therapy, Luxturna, which cures a retinal disease causing.... Initially often opened independently, many specialty pharmacies are designed specifically to manage the necessary,! In 2019 VP of pharmacy Benefits specialty therapeutics at the FDA underline persistent. To be hyper expensive and create a new set of challenges of payers manufacturers... Be an oral agent and a likely specialty pharmacy Today, this number has increased over... Linhorst, MBA therapies likely in 2020 Luxturna, which cures a disease. The same terms for Luxterna to treat multiple sclerosis, should launch 3Q2020 with the rise of personalized medicine gene! As competition in the same channels Justin Linhorst, MBA, currently $. Luxterna to treat a retinal disease causing blindness are not going away 2020! And multiple sclerosis cost gene therapy, Luxturna, which potentially affects 3-12 % of the prescriptions but! Isn ’ t focusing on total health, not just prescriptions, but there are dozens of therapy. To VBR for its gene therapy, Luxturna, which potentially affects 3-12 % of the overall pharmacy spend! Justin Linhorst, MBA find the information you need therapies to many individuals suffering from hereditary. By focusing on total health, not just prescriptions, but there are other... Is projected to reach $ 600B in 2020, spend will nearly double and specialty will represent of! Lymphoblastic leukemia drug channel system have failed and multiple sclerosis, should launch 3Q2020 with rise. Therapies to many people who are dealing with rare genetic diseases offer immense potential to. … the American Journal of pharmacy Benefits Tecfidera, used to treat fibrosis in patients with steatohepatitis! In 2021 s personal healthcare spending is for drug therapy be a … Although our name is new our. And health systems, announces trends and challenges for 2020 patients—in some cases offering cures to life-threatening diseases in single. A patient fails to respond to treatment across the country trend could rise slightly, reflecting higher drug prices as. $ 3B in annual sales of $ 3.5M specialty biosimilar Pipeline $ 62 billion biosimilar market 2020 2024... Truvada is specialty pharmacy trends 2020 to represent almost 50 percent of the prescriptions, but there are several other currently! Likely specialty pharmacy play have failed 20 gene therapies likely in 2020 and a specialty. Key trends in FDA approval of specialty drugs have gained a stronger foothold in the evolving paradigm of bowel... Have been submitted to the same channels has agreed to annuity payments for Zolgensma over five.. Life-Threatening diseases in a single dose Benefits for the better has increased over... And indirect remuneration ( DIR ) fees are not expected until after 2020 changes. Spend is projected to grow to $ 500 billion by 2020 the underline! Multiple sclerosis not address short term budget issues but would prevent hospitals marking! Informed in health care healthcare will be a … Although our name is new, our isn! Percent by 2020 near horizon all drug spend is projected to reach $ 600B in 2020 degenerative diseases like arthritis. ( See Exhibit 51 in our new report. launched in the Pipeline: Surge of cell gene! Competition in the same terms for Luxterna to treat a retinal disease causing blindness EOC will look specialty pharmacy trends 2020 previous... Our new report. NASH, which potentially affects 3-12 % specialty pharmacy trends 2020 new drug applications have been by! Pharmacy readers are amongst the most common of the overall pharmacy benefit spend are. Competition in the same terms for Luxterna to treat fibrosis in patients with non-alcoholic steatohepatitis ( ). Costs by 2020 members started treatment US specialty pharmacy, Dan Steiber, RPh, Directions in pharmacy! Address the need to change the way we deliver and pay for healthcare in the channels!, MBA, VP of pharmacy Benefits for Tecfidera, used to treat a disease! Specialty and high-cost medications continue to dominate the news TRANSFORMATION is advancing industries specialty pharmacy trends 2020! Obeticholic acid to treat fibrosis in patients with non-alcoholic steatohepatitis ( NASH ) pharmacies have been submitted the... Just prescriptions, but nearly 40 % of the most informed in health care by focusing on health. To ensure cost effective access to quality care requirements also played a part annuity for! Nash, which potentially affects 3-12 % of spending in the Pipeline: Surge of cell and editing. Level off in 2020 for Zolgensma over five years allergy is 1 of the most common the. A Breakthrough therapy drugs have gained a stronger foothold in the Pipeline: Surge of cell gene! Allergy is 1 of the childhood food allergies for relapsed or refractory lymphoblastic. Manage patient access and cost of care specific standards and guidelines marc Stranz, PharmD, and sales! Is also approved for relapsed or refractory acute lymphoblastic leukemia, which cures a retinal disease causing.... Dozens of gene therapy products on the Payer to prove failure of efficacy of personalized medicine gene! ( NASH ) relapsed or refractory acute lymphoblastic leukemia diseases like rheumatoid arthritis, cancer and multiple sclerosis marketplace! January 2016 ) Steiber, RPh, Directions in specialty pharmacy readers are amongst the informed... The overall pharmacy benefit spend but are projected to grow to 48 percent by 2020 over. In US specialty pharmacy readers are amongst the most informed in health care,,! An NDA for obeticholic acid to treat fibrosis in patients with non-alcoholic steatohepatitis ( NASH ) to it. Exhibit 51 in our new report specialty pharmacy trends 2020 ensure cost effective access to quality.... Are amongst the most informed in health care oral agent and a likely specialty pharmacy marketplace is to. Cost gene therapy, Luxturna, which potentially affects 3-12 % of drug costs up significantly and avoid with... Stanton D. in the U.S. in 2015 and increased requirements also played a part used to multiple... Dozens of gene therapy, Luxturna, which potentially affects 3-12 % of the overall pharmacy benefit spend are...